|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.77 USD | +0.82% |
|
+2.84% | -4.48% |
| 21/01 | When America Starts to Feel Like a Risky Asset |  |
| 20/01 | Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84 | MT |
Business description: BioMarin Pharmaceutical Inc.
Number of employees: 3,040
Sales by Activity: BioMarin Pharmaceutical Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Development and Commercialization of Innovative Therapies | 186.05Cr | 184.63Cr | 209.6Cr | 241.92Cr | 285.39Cr |
Geographical breakdown of sales: BioMarin Pharmaceutical Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 91Cr | 66Cr | 68Cr | 77Cr | 92Cr |
Europe | 52Cr | 56Cr | 65Cr | 67Cr | 83Cr |
Rest of World | 22Cr | 25Cr | 31Cr | 47Cr | 49Cr |
Latin America | 21Cr | 19Cr | 27Cr | 33Cr | 38Cr |
Unallocated | - | 12Cr | 13Cr | 13Cr | 18Cr |
Executive Committee: BioMarin Pharmaceutical Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 57 | 01/12/2023 |
Brian Mueller
DFI | Director of Finance/CFO | 52 | 29/01/2020 |
Gregory Friberg
CTO | Chief Tech/Sci/R&D Officer | 52 | 30/09/2024 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 05/10/2020 |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/05/2020 |
Composition of the Board of Directors: BioMarin Pharmaceutical Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Randy Meier
CHM | Chairman | 66 | 01/12/2023 |
Willard Dere
BRD | Director/Board Member | 72 | 18/07/2016 |
Robert Hombach
BRD | Director/Board Member | 60 | 29/09/2017 |
| Director/Board Member | 68 | 10/07/2019 | |
May Kin Ho
BRD | Director/Board Member | 73 | 17/02/2021 |
Alexander Hardy
BRD | Director/Board Member | 57 | 01/12/2023 |
Barbara Bodem
BRD | Director/Board Member | 58 | 27/12/2023 |
| Director/Board Member | 54 | 27/12/2023 | |
Mark Enyedy
BRD | Director/Board Member | 62 | 27/12/2023 |
Timothy Walbert
BRD | Director/Board Member | 59 | 24/02/2025 |
Company details: BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
94901, San Rafael
+415 506 6700
http://www.biomarin.com
Group companies: BioMarin Pharmaceutical Inc.
| Name | Category and Sector |
|---|---|
BioMarin International Ltd.
 BioMarin International Ltd. Develops therapeutics | |
BioMarin International Ltd.
BioMarin International Ltd. Develops therapeutics |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.82% | +2.84% | -7.74% | -48.74% | 1.08TCr | |
| +2.12% | -1.26% | +9.94% | +3.79% | 7.53TCr | |
| -2.45% | +87.30% | +87.30% | +87.30% | 6.02TCr | |
| +1.02% | +2.53% | -34.94% | -40.38% | 5.74TCr | |
| -1.37% | -0.51% | +38.08% | +229.21% | 5.72TCr | |
| +4.38% | -3.19% | +22.82% | -39.59% | 2.43TCr | |
| +2.00% | +1.20% | +45.52% | +25.81% | 2.01TCr | |
| -0.60% | -7.44% | +166.34% | +91.88% | 1.85TCr | |
| -22.35% | -21.78% | +17.27% | +998.53% | 1.74TCr | |
| +15.84% | +25.78% | +46.24% | -74.32% | 1.68TCr | |
| Average | -1.06% | -3.62% | +39.08% | +123.35% | 3.58TCr | |
| Weighted average by Cap. | -0.43% | -2.90% | +32.72% | +92.73% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMRN Stock
- Company BioMarin Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition